KIF2C exhibits elevated expression in the majority of neoplasms and demonstrates correlations with clinical prognosis, oncogenic signature gene sets, myeloid immune cell infiltration, immune scores, immune checkpoints, microsatellite instability, tumor mutational burden, and clinical outcomes across various malignancies [37]. This evidence concerns the gene KIF2C and neoplasm.